hepatic arterial infusion chemotherapy (HAIC)
Sponsors
West China Hospital, Tongji Hospital, Shandong Cancer Hospital and Institute, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University
Conditions
BCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaColorectal Liver Metastasis (CRLM)DurvalumabHAICHepatic Arterial Infusion ChemotherapyHepatic Artery Infusion ChemotherapyHepatocellular Carcinoma
Phase 2
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)
RecruitingNCT06859684
Start: 2025-03-01End: 2027-03-06Target: 25Updated: 2026-03-09
FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis
RecruitingNCT06988852
Start: 2023-05-01End: 2030-12-31Target: 300Updated: 2025-05-25
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases
RecruitingNCT07062055
Start: 2025-07-25End: 2029-07-25Target: 54Updated: 2026-04-01
HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC
CompletedNCT07304388
Start: 2023-02-10End: 2025-06-01Updated: 2025-12-30
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Not yet recruitingNCT07353827
Start: 2026-02-01End: 2028-12-31Target: 36Updated: 2026-01-20